CD40激动剂改善了由放射治疗加上CTLA4抑制的组合诱导的抗肿瘤T细胞启动，并增强了肿瘤反应。

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-09-15 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2258011

Maud Charpentier, Silvia Formenti, Sandra Demaria

引用次数: 0

摘要

放射治疗（RT）联合CTLA4阻断剂将免疫抑制（冷）小鼠三阴性乳腺癌（TNBCs）转化为免疫浸润（热）病变。我们最近已经表明，大多数携带TNBC的小鼠需要靶向髓细胞隔室以改善树突状细胞活化，才能对RT加CTLA4抑制剂产生优异的治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response.

查看原文本刊更多论文

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response.

Radiation therapy (RT) combined with CTLA4 blockers converts immunosuppressed (cold) mouse triple negative breast cancers (TNBCs) into immune infiltrated (hot) lesions. We have recently shown that targeting the myeloid compartment to improve dendritic cell activation is required for most TNBC-bearing mice to achieve superior therapeutic responses to RT plus CTLA4 inhibitors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.